Clinical trials: Von Willebrand Diseases, open to volunteers
Thrombotic Thrombocytopenic Purpura, Congenital Thrombotic Thrombocytopenic Purpura
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
Hereditary thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) is a rare disorder characterized by thrombocytopenia as a result of platelet consumption, microangiopathic hemolytic anemia, occlusion of the…
- Conditions
- Thrombotic Thrombocytopenic Purpura, Congenital Thrombotic Thrombocytopenic Purpura, Familial Thrombotic Thrombocytopenic Purpura, Thrombotic Thrombocytopenic Purpura, Congenital
- Trial name
- TTP registry (NCT01257269)
- Testing
- Observation
- Where
- 7 sites in United States, Austria and 5 more
- Volunteers
- 450 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Von Willebrand Disease (VWD)
A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)
The main aim of this study is to find out if VONVENDI is safe for adult Chinese participants with VWD. The study will also check how well VONVENDI helps control bleeding with or without product ADVATE in the participants who may…
- Trial name
- NCT07129343
- Testing
- VONVENDI, ADVATE
- Where
- 7 sites in China
- Volunteers
- 20 people
- Sponsor
- Takeda
Von Willebrand Disease, Type 3
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
This is a Phase III, multicenter, open-label clinical study designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab prophylaxis in participants aged 1 month and above, who have been…
- Trial name
- WILL-EMI (NCT06998524)
- Testing
- Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates
- Where
- 29 sites in United States, Belgium and 12 more
- Volunteers
- 75 people
- Sponsor
- Hoffmann-La Roche
Von Willebrand Diseases, Major Constitutional Thrombopathy
Development of a Device for Evaluating Primary Hemostasis Under Whole Blood Flow Conditions
Currently, the exploration of primary hemostasis (a physiological phenomenon used to stop bleeding) is imperfect because it is based on targeted tests for platelets or von Willebrand factor, without taking into account blood flow…
- Conditions
- Von Willebrand Diseases, Major Constitutional Thrombopathy, Patient on Antiplatelet Drugs
- Trial name
- INDONESIA (NCT03773159)
- Testing
- Blood sampling
- Where
- 2 sites in France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1
A Study Assessing HMB-002 in Participants With Von Willebrand Disease
This is a first-in-human (FIH), Phase 1/2, 3-part open-label, dose escalation, safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and efficacy study evaluating HMB-002 in participants with VWD.
- Conditions
- Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
- Trial name
- NCT06754852
- Testing
- HMB-002 (Part A), HMB-002 (Part B), HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US)
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 108 people
- Sponsor
- Hemab ApS
Perioperative Bleeding, Coagulopathy During Cardiac Surgery
Flow-Based Platelet Function Assessment Using Total Thrombus-Formation Analysis System (T-TAS) and Early Bleeding After Cardiac Surgery With Cardiopulmonary Bypass (CPB)
The goal of this observational study is to learn how flow-based platelet function measured with the Total Thrombus-formation Analysis System (T-TAS) relates to early postoperative bleeding in adults undergoing cardiac surgery…
- Conditions
- Perioperative Bleeding, Coagulopathy During Cardiac Surgery, Platelet Dysfunction, Cardiac Surgery
- Trial name
- TTAS-CPB (NCT07619261)
- Testing
- Total Thrombus-formation Analysis System (T-TAS)
- Volunteers
- 30 people
- Sponsor
- Hospital de la Santa creu i Sant Pau - Barcelona
Von Willebrand Disease (VWD), Acquired Von Willebrand Disease
Endothelial Colony-Forming Cells in Patients With VWD, AVWS and Healthy Subjects
The goal of this observational study is to learn how endothelial colony-forming cells (ECFCs) behave in people with von Willebrand disease (VWD), acquired von Willebrand syndrome (AVWS), and in healthy individuals.
- Trial name
- ECFCs/2022 (NCT07358013)
- Testing
- Blood sample collection for VWF measurements in plasma, Blood sample collection for ECFC isolation and characterization, Genetic testing of VWF
- Where
- Italy
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Von Willebrand Disease (VWD), Inherited Bleeding Disorders in Children
Clinical Spectrum and Management of Von Willebrand Disease Among Children in Assiut Governorate
Von Willebrand disease (VWD) is the most common inherited bleeding disorder in children. It occurs due to a deficiency or dysfunction of von Willebrand factor, a protein that plays an essential role in blood clotting.
- Conditions
- Von Willebrand Disease (VWD), Inherited Bleeding Disorders in Children, Pediatric Hemostatic Disorders
- Trial name
- VWD-ASSIUT (NCT07410130)
- Testing
- Tranexamic Acid, Von Willebrand Factor-Containing Concentrates
- Where
- Egypt
- Volunteers
- 25 people
- Sponsor
- Assiut University
Von Willebrand Diseases
Cardiovascular and Venous Thromboembolism Disease in Patients with Von Willebrand Disease in the French West
Due to increasing of life expectancy, patients with von Willebrand disease are exposed to age-related pathologies such as cancer or cardiovascular diseases.
- Trial name
- TWIGO (NCT05773638)
- Where
- 6 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Brest
Liver Cirrhosis, Portal Hypertension
Von Willebrand Factor Levels in Patients With Liver Cirrhosis and Portal Hypertension
Verify Von willebrand factor role in patients with liver cirrhosis and portal hypertension
- Trial name
- NCT06694090
- Volunteers
- 67 people
- Sponsor
- Assiut University
Cerebral Microbleeds, Congenital Haemophilia, Congenital Von Willebrand Disease
Severe Congenital Hemostatic Defects, Cerebral MIcrobleeds and COGnition
Cerebral microbleeds (CMBs) are haemosiderin deposits, resulting from the leakage of erythrocytes from small cerebral vessels, which can be detected noninvasively using susceptibility-sensitive magnetic resonance imaging (MRI)…
- Trial name
- HEMICOG (NCT06090201)
- Testing
- 3-Tesla brain MRI and a comprehensive neuropsychological assessment
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Lille
Von Willebrand Diseases
A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients With VWD
The EMPOWER trial is a pilot multi-center, placebo-controlled (normal saline), double-blind (patient and outcome assessor), crossover, 2-year randomized trial in female outpatients with von Willebrand disease (VWD) and heavy…
- Trial name
- EMPOWER (NCT06205095)
- Testing
- Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- Unity Health Toronto
Coronary Artery Disease, Percutaneous Coronary Intervention
Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.
Patients who undergo percutaneous coronary intervention (PCI) are commonly treated with antiplatelet therapy to prevent stent thrombosis and recurrence of events.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndromes, Antiplatelet Therapy
- Trial name
- HI-TECH 2 (NCT07582835)
- Testing
- Clopidogrel, Ticagrelor, Prasugrel
- Where
- Switzerland
- Volunteers
- 355 people
- Sponsor
- Cardiocentro Ticino
Heavy Menstrual Bleeding, Bleeding Disorder
Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study
The goal of this multicenter prospective observational study and registry of U.S. adolescents and young adults with heritable bleeding disorders is to determine the bleeding outcomes, satisfaction, hemostatic parameter changes…
- Conditions
- Heavy Menstrual Bleeding, Bleeding Disorder, Von Willebrand Diseases
- Trial name
- HMB-BD (NCT05916469)
- Testing
- Levonorgestrel Intrauterine System, Norethindrone Acetate
- Where
- 8 sites in United States
- Volunteers
- 300 people
- Sponsor
- Oregon Health and Science University
Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB)
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB
- Trial name
- HMBeacon (NCT07575308)
- Testing
- ALN-6400
- Where
- 21 sites in United States, Netherlands and 3 more
- Volunteers
- 24 people
- Sponsor
- Alnylam Pharmaceuticals
Coagulation Disorder, Blood, Prolonged APTT
External Multicenter Validation of the APTTO Model for Prolonged APTT Using Clot Waveform Analysis
Prolonged activated partial thromboplastin time (APTT) is a frequent laboratory finding that may reflect a broad spectrum of underlying conditions, ranging from benign laboratory abnormalities to clinically relevant hemostatic…
- Trial name
- APTTO-EXT (NCT07418099)
- Testing
- Clot waveform analysis-based risk stratification (APTTO models)
- Where
- 16 sites in Spain
- Volunteers
- 1,500 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
VWD - Von Willebrand's Disease
The Severe Von Willebrand Disease (sVWD) Patient Registry
A web-based registry will be created by the sponsor, VWD Connect Foundation (VCF), to collect data on patients with severe Von Willebrand Disease (sVWD).
- Trial name
- NCT05437536
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- VWD Connect Foundation
Von Willebrand Disease (vWD)
An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)
This study is conducted in Japan of vonicog alfa (rVWF) used to treat pediatric participants with Von Willebrand Disease (vWD). The main aim of the study is to evaluate adverse drug reaction and effectiveness of vonicog alfa…
- Trial name
- NCT07404644
- Testing
- vonicog alfa (rVWF)
- Where
- Japan
- Volunteers
- 13 people
- Sponsor
- Takeda
Bleeding Disorder
Recombinant vWF Concentrate and ECMO
Adult patients on extracoporeal membrane oxygenation (ECMO) frequently experience bleeding, which is in part caused by acquired von Willebrand syndrome (vWS).
- Trial name
- NCT06118372
- Testing
- Recombinant von Willebrand Factor
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Virginia
Von Willebrand Disease (VWD)
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)
- Trial name
- VIVID-6 (NCT07115004)
- Testing
- VGA039
- Where
- 32 sites in United States, Australia and 8 more
- Volunteers
- 60 people
- Sponsor
- Vega Therapeutics, Inc